News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

SensiGen LLC Receives Investment from Delaware Crossing


10/23/2007 8:34:37 AM

ANN ARBOR, Mich. & PHILADELPHIA--(BUSINESS WIRE)--SensiGen LLC, a biotechnology company developing proprietary gene-based molecular diagnostics announced today the closing of a $300,000 investment from Delaware Crossing Investor Group, a Mid-Atlantic region angel investor group. The funds will be used to help SensiGen accelerate development and commercialization of the Company’s revolutionary AttoSense™ molecular diagnostic technology.

Read at BioSpace.com

comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES